TYK2 licenses non-canonical inflammasome activation during endotoxemia

被引:0
作者
Andrea Poelzl
Caroline Lassnig
Simone Tangermann
Dominika Hromadová
Ursula Reichart
Riem Gawish
Kristina Mueller
Richard Moriggl
Andreas Linkermann
Martin Glösmann
Lukas Kenner
Mathias Mueller
Birgit Strobl
机构
[1] University of Veterinary Medicine Vienna,Institute of Animal Breeding and Genetics
[2] University of Veterinary Medicine Vienna,Biomodels Austria
[3] University of Veterinary Medicine Vienna,Unit of Laboratory Animal Pathology
[4] University of Veterinary Medicine Vienna,VetCORE
[5] University Hospital Carl Gustav Carus at the Technische University of Dresden, Facility for Research
来源
Cell Death & Differentiation | 2021年 / 28卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The non-canonical inflammasome is an emerging crucial player in the development of inflammatory and neurodegenerative diseases. It is activated by direct sensing of cytosolic lipopolysaccharide (LPS) by caspase-11 (CASP11), which then induces pyroptosis, an inflammatory form of regulated cell death. Here, we report that tyrosine kinase 2 (TYK2), a cytokine receptor-associated kinase, is a critical upstream regulator of CASP11. Absence of TYK2 or its kinase activity impairs the transcriptional induction of CASP11 in vitro and in vivo and protects mice from LPS-induced lethality. Lack of TYK2 or its enzymatic activity inhibits macrophage pyroptosis and impairs release of mature IL-1β and IL-18 specifically in response to intracellular LPS. Deletion of TYK2 in myeloid cells reduces LPS-induced IL-1β and IL-18 production in vivo, highlighting the importance of these cells in the inflammatory response to LPS. In support of our data generated with genetically engineered mice, pharmacological inhibition of TYK2 reduced LPS-induced upregulation of CASP11 in bone marrow-derived macrophages (BMDMs) and of its homolog CASP5 in human macrophages. Our study provides insights into the regulation of CASP11 in vivo and uncovered a novel link between TYK2 activity and CASP11-dependent inflammation.
引用
收藏
页码:748 / 763
页数:15
相关论文
共 358 条
  • [1] Fuchs S(2016)Tyrosine kinase 2 is not limiting human antiviral type III interferon responses Eur J Immunol 46 2639-49
  • [2] Kaiser-Labusch P(2015)Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome J Exp Med 212 1641-62
  • [3] Bank J(2011)Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity Front Biosci (Landmark Ed) 16 3214-32.
  • [4] Ammann S(2017)Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene Cytokine 89 209-18
  • [5] Kolb-Kokocinski A(2019)Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018) Expert Opin Ther Pat 29 137-49
  • [6] Edelbusch C(2018)Phase 2 trial of selective tyrosine Kinase 2 inhibition in psoriasis N. Engl J Med 379 1313-21
  • [7] Kreins AY(2013)Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent J Immunol 190 2335-44
  • [8] Ciancanelli MJ(2015)In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity Oncoimmunology 4 e1047579-57
  • [9] Okada S(2017)Kinase Inactive Tyrosine Kinase (Tyk2) supports differentiation of brown fat cells Endocrinology 158 148-36
  • [10] Kong XF(2013)The inflammatory response in sepsis Trends Immunol 34 129-65